Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

Female patients with stage II or III (cT1cN+ or ≥T2 any cN, cM0) breast cancer. - Planned to receive standard neoadjuvant chemotherapy.
Measurable disease (breast and/or lymph nodes).
WHO performance status 0-2.
Being overweight (BMI: 25-29.9 kg/m2) or obese (BMI: ≥30 kg/m2).
Adequate bone marrow function : white blood cells (WBCs) ≥3.0 x 109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l
Adequate liver function: bilirubin ≤1.5 x upper limit of normal (UNL) range, ALAT and/or ASAT ≤2.5 x UNL, Alkaline Phosphatase ≤5 x UNL
Adequate renal function: the calculated creatinine clearance should be ≥50 mL/min
Patients must be accessible for treatment and follow-up

Serious diseases such as recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias
Diabetes Mellitus.
Pregnancy or lactating
Any metabolic disorders that may affect gluconeogenesis or adaptation to fasting periods.
Previous malignancy.
Using weight loss medication.

Influence of Intermittent Fasting on Locally Advanced Breast Cancer Patients